Israel Englander’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Israel Englander’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-706,893	Closed	-$7.14M	–	7388
2022 Q4	$7.14M	Hold	706,893	–	–	﹤0.01%	2489
2022 Q3	$7.01M	Buy	706,893 +247,997	+54%	+$2.45M	﹤0.01%	2557
2022 Q2	$4.54M	Sell	458,896 -142,155	-24%	-$1.39M	﹤0.01%	2905
2022 Q1	$5.93M	Buy	601,051 +467,900	+351%	+$4.61M	﹤0.01%	2749
2021 Q4	$1.31M	Hold	133,151	–	–	﹤0.01%	4151
2021 Q3	$1.3M	Buy	133,151 +96,000	+258%	+$930K	﹤0.01%	4400
2021 Q2	$359K	Buy	+37,151	New	+$361K	﹤0.01%	5594

Israel Englander's BIOT Position: Q1 2023 in Review

Israel Englander sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 706,893 shares — an estimated $7.14M sold.

Israel Englander first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $7.14M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Israel Englander reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Israel Englander sold 706,893 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $7.14M.
Israel Englander first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Israel Englander's Biotech Acquisition Company Class A Ordinary Shares position peaked at $7.14M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.